Sergio Marchini - Concepedia

Author

Sergio Marchini

Mario Negri Institute for Pharmacological Research ORCID

Also Known As

Bentham Science Publisher Marchini S., Marchini, Sergio, Marchini, sergio, Maurizio D’Incalci, S Marchini, S V Marchini, S, Marchini, S. Marchini, Sergio M. Marchini, Sergio Marchini

331

Publications

Citations

H-Index

118

Concepts

All Affiliations

Mario Negri Institute for Pharmacological Research Istituti di Ricovero e Cura a Carattere Scientifico University of Padua University of Milano-Bicocca University of Milan

About

Sergio Marchini is an author at Mario Negri Institute for Pharmacological Research specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	45	3.8K
2	Natural Sciences	6	6	339
3	Engineering	2	2	39
4	Health Sciences	2	2	71
5	Public Health	1	1	18

Sergio Marchini

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin Giovanni Germano, Roberta Frapolli, Cristina Belgiovine, Cancer Cell Cancer ImmunosurveillanceDrug TargetingImmunologyImmunotherapyMedicine	2013	847
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Dorina Belotti, Paola Paganoni, Luigi Manenti, PubMed PathologyCancer BiologyMmp Inhibitor BatimastatTumor BiologyOvarian Cancer	2003	320
microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition Aditya Parikh, Christine Lee, Peronne Joseph, Nature Communications	2014	262
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743 Mario Minuzzo, Sergio Marchini, Massimo Broggini, Proceedings of the National Academy of Sciences Transcriptional RegulationMedicinal ChemistryTunicate Ecteinascidia TurbinataOncogenic AgentMedicine	2000	195
Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy Valentina Iori, Anand M. Iyer, Teresa Ravizza, Neurobiology of Disease Il-1r1/tlr4 PathwayMedicineImmunologyNeurological ProgressAutoimmunity	2016	180
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections Sergio Marchini, Duccio Cavalieri, Robert Fruscio, The Lancet Oncology Retrospective StudyEpithelial Ovarian CancerMedicinePathologyGynecology	2011	178
Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy Francesco M. Noè, N. Polascheck, Federica Frigerio, Neurobiology of Disease NeurophysiologyMedicinePharmacologyRat ModelsPharmacological Blockade	2013	171
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer Sergio Marchini, Robert Fruscio, Luca Clivio, European Journal of Cancer Epithelial Ovarian CancerMedicineMesenchymal TransitionCancer GrowthCancer Biology	2012	170
A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Giuseppina Della Vittoria Scarpati, Francesca Falcetta, Chiara Carlomagno, International Journal of Radiation OncologyBiologyPhysics Complete Pathological ResponseSpecific Mirna SignatureOncologyNeoadjuvant ChemoradiotherapyMedicine	2011	152
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models Cristina Belgiovine, Ezia Bello, Manuela Liguori, British Journal of Cancer	2017	149

Page 1